Compare Devonian Health Group, Inc. with Similar Stocks
Dashboard
1
With a fall in Net Profit of -59.62%, the company declared Very Negative results in Apr 26
- The company has declared negative results for the last 4 consecutive quarters
- The company has declared negative results in Jul 25 after 7 consecutive negative quarters
- NET SALES(HY) At CAD 0.66 MM has Grown at -95.9%
- PRE-TAX PROFIT(Q) At CAD -1.94 MM has Fallen at -5,538.8%
- NET PROFIT(Q) At CAD -1.94 MM has Fallen at -5,538.8%
2
Risky -
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CAD 25 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.09
-87.61%
3.59
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Apr 2026)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3129.17%
0%
3129.17%
6 Months
3775.0%
0%
3775.0%
1 Year
5435.71%
0%
5435.71%
2 Years
3590.48%
0%
3590.48%
3 Years
1191.67%
0%
1191.67%
4 Years
1481.63%
0%
1481.63%
5 Years
6358.33%
0%
6358.33%
Devonian Health Group, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
35.98%
EBIT Growth (5y)
-6.91%
EBIT to Interest (avg)
-2.99
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.10
Sales to Capital Employed (avg)
1.59
Tax Ratio
0.21%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.64%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.43
EV to EBIT
-6.04
EV to EBITDA
-6.41
EV to Capital Employed
3.87
EV to Sales
2.54
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-64.08%
ROE (Latest)
-52.38%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Apr'26 - YoY
Apr'26
Apr'25
Change(%)
Net Sales
0.20
7.40
-97.30%
Operating Profit (PBDIT) excl Other Income
-1.90
0.10
-2,000.00%
Interest
0.00
0.00
Exceptional Items
0.00
-4.80
100.00%
Consolidate Net Profit
-1.90
-4.80
60.42%
Operating Profit Margin (Excl OI)
-10,962.30%
-4.10%
-1,095.82%
USD in Million.
Net Sales
YoY Growth in quarter ended Apr 2026 is -97.30% vs 45.10% in Apr 2025
Consolidated Net Profit
YoY Growth in quarter ended Apr 2026 is 60.42% vs -1,100.00% in Apr 2025
Annual Results Snapshot (Consolidated) - Jul'25
Jul'25
Jul'24
Change(%)
Net Sales
23.60
19.30
22.28%
Operating Profit (PBDIT) excl Other Income
-0.40
0.10
-500.00%
Interest
0.30
0.40
-25.00%
Exceptional Items
-4.80
0.00
Consolidate Net Profit
-6.00
-1.80
-233.33%
Operating Profit Margin (Excl OI)
-32.70%
-31.80%
-0.09%
USD in Million.
Net Sales
Not Applicable: The company has declared_date for only one period
Consolidated Net Profit
Not Applicable: The company has declared_date for only one period
About Devonian Health Group, Inc. 
Devonian Health Group, Inc.
Pharmaceuticals & Biotechnology
Devonian Health Group In is a late stage Canada-based botanical and pharmaceutical company. The Company adopts a therapeutic approach, which targets various worldwide unmet medical needs. The core business of the Company is the development of prescription botanical drugs, as well as derma-cosmeceutical products, which is divided into two main segments: Therapeutics and Derma-cosmeceuticals. The Therapeutics segment includes Thykamine, which is an active lead drug candidate confirmed in a number of pre-clinical and clinical studies targeting inflammation. The Derma-cosmeceuticals includes the first derma-cosmeceutical product of the Company, which is a women’s anti-aging treatment consisting of day, night and eye creams.
Company Coordinates 
Company Details
115 Frontenac Ave , POINTE-CLAIRE QC : H9R 4Z7
Registrar Details






